Q-omics provides the consensus-scored ESRRAP2 profile across patient tissues and cancer cell-line models. ESRRAP2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ESRRAP2 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, ESRRAP2 RNA expression shows 17,616 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where ESRRAP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ESRRAP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ESRRAP2 survival associations across molecular data types. ESRRAP2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ESRRAP2 RNA expression–survival associations across cancer types. High ESRRAP2 expression shows unfavorable associations in LGG, CESC and KICH, but favorable associations in KIRC, BRCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ESRRAP2 RNA expression.
This table summarizes ESRRAP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ESRRAP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ESRRAP2 shows lower tumor expression in THCA, KIRC, KICH, BRCA and KIRP and higher tumor expression in LIHC. The THCA box plot shows higher ESRRAP2 RNA expression in normal versus tumor tissue (log2 FC = −0.724, t-test p < 0.001).
This table shows molecular features associated with ESRRAP2 in patient tissues and cancer cell lines. In patient samples, ESRRAP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
